Our firm is GFB-024, an innovative anti- CB1 antibody developed mainly regarding academic purposes. This reagent exhibits high affinity towards cannabinoid receptor, enabling thorough analyses into the receptor’s role regarding various cellular pathways. This reagent can be applied during a spectrum applications, such as receptor evaluations alon